This program aims to study disease mechanisms for three major disorders affecting women’s health: breast cancer, ovarian cancer and osteoporosis. The development and evolution of these disorders show certain interrelationships that suggest common underlying mechanisms. The simultaneous study of the three disorders promises to lead to the identification of new molecular targets for the diagnosis and treatment of these serious health problems in women. This program is led by Alethia BioTherapeutics Inc., in collaboration with a network of leading academic scientists in the province of Québec.
Co-applicants:
| Anne-Marie | Mes-Masson | Université de Montréal |
| Morag | Park | Royal Victoria Hospital |
| Patricia | Tonin | Montreal General Hospital |